



## Biomaterials for Cancer Immunotherapy

Guest Editor:

**Prof. Dr. Jayanth Panyam**

Professor and Dean, Temple  
University School of Pharmacy,  
3307 North Broad Street,  
Philadelphia, PA 19140, USA

Deadline for manuscript  
submissions:

**closed (1 November 2021)**

### Message from the Guest Editor

Dear Colleagues,

The goal of cancer immunotherapy is to activate the host immune system to recognize and eliminate malignant cells. The term immunotherapy is used broadly to include various vaccine modalities, cytokines, CAR-T cells, NK cell therapies, antibodies that mediate antibody-dependent cellular cytotoxicity, checkpoint inhibitors, oncolytic viruses, and immunomodulators that reverse tumor-induced immunosuppression.

Biomaterials can improve the effectiveness of immunotherapy by facilitating selective and improved delivery of the active agent to the target cells and tissue. Enhanced activation of antigen-presenting cells by delivering immunostimulants in nanocarriers and improved activity of checkpoint inhibitors following local sustained delivery are some examples. The focus of this Special Issue on “Biomaterials for Cancer Immunotherapy” is to further highlight, through original research articles as well as comprehensive reviews, the use of biomaterials to improve the safety and efficacy of anticancer immunotherapy.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)